Taken together, these studies suggest that PGRN lies at the intriguing interface between metabolic disorders and ALS/FTLD, whereby its deficiency is associated with neurodegeneration and its increase is associated with metabolic perturbations. This evidence concerns the gene GRN and amyotrophic lateral sclerosis.